Skrr Exploration, Inc.TSXV: SKRR

Biomira President & CEO to Participate in Cancer Immunotherapy Focus Session at BIO CEO & Investor Conference

· Issued by Skrr Exploration, Inc. via CNW
EDMONTON, Feb. 8 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today
announced that Alex McPherson, MD, Ph.D., President and Chief Executive
Officer, is scheduled to participate in a focus session entitled "Cancer
Immunotherapies Coming of Age" at the Biotechnology Industry Organization's
8th Annual BIO CEO & Investor Conference at 9:00 a.m. EST on Tuesday,   
February 14, 2006. The conference is to be held at The Waldorf-Astoria in   
New York City.
Dr. McPherson will be joined on the panel by John P. Longenecker, PhD,
President & CEO, Favrille Inc., Peter Working, PhD, Senior Vice President,
Research and Development, Cell Genesys, Inc., Mitchell Gold, MD, President and
CEO, Dendreon Corporation, and Hyam Levitsky, MD, Professor of Oncology, Johns
Hopkins University School of Medicine. Mark Monane, MD, Managing Director of
Equity Research, Biotechnology and Life Sciences, Needham and Company, LLC,
will serve as the panel's moderator.
A webcast recording of the focus session can be accessed at
http://ceo.bio.org/opencms/ceo/2006/index.jsp. The Web cast recording will be
available approximately 12 hours after the presentation and will be archived
until March 14, 2006.

About Biomira
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's commitment
to the treatment of cancer currently focuses on the development of synthetic
vaccines and novel strategies for cancer immunotherapy.


Company analysis